NVAX

In the past six months, Novavax's stock price has been influenced by several key events, underperforming the S&P500 Index by -19.47%. As of September 24, 2026, the share price was $10.49, trading between $6.20 and $11.97 over the past 52 weeks. The Q2 2026 Earnings Report on August 6, 2026, showed a 76% decrease in total revenue to $57 million, primarily due to reduced milestone revenue, though product sales increased by 76% to $19 million. The company reported a net loss of $53 million, a decline from a net income of $107 million in Q2 2025, but raised its 2026 Adjusted Total Revenue framework to $235–$275 million. On August 27, 2026, FDA approval of updated COVID vaccines from Moderna, Pfizer, and Novavax likely contributed to positive stock movement. A major estimate revision on August 5, 2026, saw consensus EPS estimates for fiscal year 2026 fall by 17%, with decreased revenue forecasts and increased expected losses. Shareholder dissent escalated at Novavax's AGM on June 24, 2026, with demands for leadership changes. The May 2024 Sanofi partnership continues to be a significant factor, providing immediate cash, future milestone potential, and access to Sanofi's commercial scale, with Novavax eligible for up to $125 million in Phase 3 CIC trial initiation milestones and an expected $75 million manufacturing tech transfer milestone around mid-2027.